## Lambros Kordelas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8672942/publications.pdf

Version: 2024-02-01

567281 1,894 34 15 citations h-index papers

28 g-index 35 35 35 4027 docs citations times ranked citing authors all docs

501196

#	Article	IF	CITATIONS
1	Pre-Transplant Serum Leptin Levels and Relapse of Acute Myeloid Leukemia after Allogeneic Transplantation. International Journal of Molecular Sciences, 2022, 23, 2337.	4.1	1
2	Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Annals of Hematology, 2021, 100, 959-968.	1.8	34
3	EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 553-561.	2.4	70
4	Allogeneic transplantation of peripheral blood stem cell grafts results in a massive decrease of primitive hematopoietic progenitor frequencies in reconstituted bone marrows. Bone Marrow Transplantation, 2020, 55, 100-109.	2.4	1
5	Optimizing anti-T-lymphocyte globulin dosing to improve long-term outcome after unrelated hematopoietic cell transplantation for hematologic malignancies. American Journal of Transplantation, 2020, 20, 677-688.	4.7	9
6	Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation. Cancers, 2020, 12, 2789.	3.7	7
7	Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation. Haematologica, 2020, 105, 1454-1464.	3.5	2
8	Rapid Rebound of a Preexisting CXCR4-tropic Human Immunodeficiency Virus Variant After Allogeneic Transplantation With CCR5 î"32 Homozygous Stem Cells. Clinical Infectious Diseases, 2019, 68, 684-687.	5.8	42
9	Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice. Scientific Reports, 2019, 9, 12914.	3.3	4
10	Individual Immune-Modulatory Capabilities of MSC-Derived Extracellular Vesicle (EV) Preparations and Recipient-Dependent Responsiveness. International Journal of Molecular Sciences, 2019, 20, 1642.	4.1	36
11	Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study. EBioMedicine, 2019, 49, 202-212.	6.1	11
12	Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation. Haematologica, 2019, 104, 827-834.	3.5	4
13	Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival. Frontiers in Immunology, 2019, 10, 3027.	4.8	7
14	Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation with Venetoclax, Hypomethylating Agents and DLI - a Retrospective Multi Center Study. Blood, 2019, 134, 4563-4563.	1.4	3
15	High Pre-Transplant Free Interleukin-18 Is Associated with Poor Hematopoietic Recovery after Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 4507-4507.	1.4	0
16	Highâ€dose melphalanâ€based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology, 2018, 180, 840-853.	2.5	15
17	Elevated soluble human leukocyte antigen G levels in patients after allogeneic stem cell transplantation are associated with less severe acute and chronic graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 1149-1156.	2.4	9
18	Pre-Conditioning Serum Leptin Levels Predict Early Relapse Rates of High Risk AML after Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 3419-3419.	1.4	0

#	Article	IF	CITATIONS
19	Intestinal T lymphocyte homing is associated with gastric emptying and epithelial barrier function in critically ill: a prospective observational study. Critical Care, 2017, 21, 70.	5.8	20
20	Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. Journal of Clinical Oncology, 2017, 35, 3143-3152.	1.6	27
21	Clinical potential of mesenchymal stem/stromal cell-derived extracellular vesicles. Stem Cell Investigation, 2017, 4, 84-84.	3.0	131
22	The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease. International Journal of Molecular Sciences, 2016, 17, 1797.	4.1	30
23	CD34+ highly enriched allogeneic stem cell transplantation in a patient with mixed phenotype acute leukemia and Fusarium solani sepsis. Annals of Hematology, 2016, 95, 155-156.	1.8	3
24	Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial. Blood, 2016, 128, 502-502.	1.4	11
25	Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper. Journal of Extracellular Vesicles, 2015, 4, 30087.	12.2	1,020
26	<scp>CD</scp> 133 allows elaborated discrimination and quantification of haematopoietic progenitor subsets in human haematopoietic stem cell transplants. British Journal of Haematology, 2015, 169, 868-878.	2.5	31
27	More on Shift of HIV Tropism in Stem-Cell Transplantation with <i>CCR5 </i> Delta 32/Delta 32 Mutation. New England Journal of Medicine, 2014, 371, 2437-2438.	27.0	69
28	Shift of HIV Tropism in Stem-Cell Transplantation with <i>CCR5</i> Delta32 Mutation. New England Journal of Medicine, 2014, 371, 880-882.	27.0	144
29	Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study. Haematologica, 2012, 97, 1523-1531.	3.5	116
30	Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica, 2010, 95, 388-397.	3.5	20
31	Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Clinical Outcome and Immune Reconstitution Blood, 2009, 114, 1203-1203.	1.4	0
32	Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab. Oncology Research and Treatment, 2008, 31, 691-693.	1.2	17
33	Improved Overall Survival in Patients Recovering with High Gamma/Delta T Cells after Allogeneic Haematopoietic Stem Cell Transplantation Blood, 2008, 112, 2223-2223.	1.4	0
34	Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: Interim Analysis of a Phase I/II Study Blood, 2008, 112, 1962-1962.	1.4	0